Delivery order for pluvicto and lutathera
Ended Awarded Last action
- Contract number
- W81K0024F0177
- Awardee
-
Novartis Pharmaceuticals Corporation UEI NG61ZA8TADW3
- Awarding agency
-
Medical Command
Department of the Army, Department of Defense
- Obligated
- $3,387,020
Award facts
- Opportunity
-
- RADIOPHARMACEUTICALS (LUTATHERA and PLUVICTO) Pre-Solicitation · W81K0024R0020 · Posted Apr 26, 2024
- Contract value 100% obligated
- $3,387,019.66 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- Funding agency
- Defense Health Agency Department of Defense
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Not Competed Only One Source
- Pricing
- Fixed Price with Economic Price Adjustment
- Place of performance
- 2330 Stanley Rd, Fort Sam Houston, TX 78234, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $23,462 | |
| Funding Only Action | $3,363,558 | |
| Original award | $0 |
About this award
The Defense Health Agency awarded a delivery order to Novartis Pharmaceuticals Corporation on October 1, 2024, for the supply of PLUVICTO (Lutetium Lu-177 Vipivotide Tetraxetan) and LUTATHERA (Lutetium Lu-177 dotatate), specialized radiopharmaceutical cancer therapies used in advanced oncology treatment. This fixed-price delivery order with economic price adjustment carries a ceiling value of $3.39M and is scheduled for completion by September 30, 2025. The order will be delivered to Fort Sam Houston, Texas, and is not designated as a small business set-aside, reflecting Novartis' status as a large pharmaceutical manufacturer competing directly in the federal marketplace.
This delivery order is issued under a larger Indefinite Delivery Contract vehicle with the Defense Health Agency, awarded October 1, 2024, with a total ceiling value of $26.10M extending through September 30, 2029. The parent contract authorizes the procurement of both Lutathera and Pluvicto for federal healthcare systems and supports the Department of Defense's medical treatment mission. Novartis has established itself as a major federal supplier of specialized oncology and radiopharmaceutical treatments, with extensive prior contract history serving the Department of Veterans Affairs and Defense Health Agency across multiple facilities nationwide.
Quick answers
Who was awarded contract W81K0024F0177?
W81K0024F0177 was awarded to Novartis Pharmaceuticals Corporation by Medical Command (Department of the Army) on October 1, 2024.
How much is contract W81K0024F0177 worth?
The government has obligated $3,387,020 on W81K0024F0177.
Which agency awarded contract W81K0024F0177?
Medical Command (Department of the Army) awarded W81K0024F0177, with funding from Defense Health Agency (Department of Defense).
Is contract W81K0024F0177 an order under another contract?
Yes. W81K0024F0177 is a delivery order under W81K0024D0004, an indefinite delivery contract.
Was contract W81K0024F0177 competed?
The extent of competition for W81K0024F0177 was not competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award